Other examples include Vitamin A conjugation to liposomes (ND‐L02‐s0201) to target delivery of siRNA to stellate cells in the liver to treat hepatic fibrosis.83 A HER‐2 targeted PEGylated liposomal doxorubicin (MM‐302) for treatment of breast cancer is also being developed.93 This builds on the success of FDA‐approved and HER‐2 targeted monoclonal antibody Herceptin (trastuzumab)94, 95 and the more recently approved antibody drug conjugate version (Kadcyla).96, 97 Other systems use bi‐specific antibodies to target delivery of mRNA therapeutics (TargomiRs). The gene discussed is ERBB2; the disease is breast carcinoma.